Oncomatryx Biopharma Revenue and Competitors

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.\r\n\r\nOncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma.\r\n\r\nOncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression.\r\n\r\nOncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.